The Healthcare Business of Merck KGaA, Darmstadt, Germany Standardizes on Veeva CRM Globally to Improve Commercial Execution Across Channels

Expansion in EMEA follows the business’ success with Veeva CRM
throughout North America, Latin America, and Asia Pacific

PLEASANTON, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CRM?src=hash" target="_blank"gt;#CRMlt;/agt;–Veeva
Systems (NYSE:VEEV) today announced that the Healthcare business of Merck
KGaA, Darmstadt, Germany has selected Veeva
CRM to improve operating efficiency and commercial effectiveness in
Europe, Middle East, and Africa (EMEA). Building on the multi-year
partnership with Veeva and following its success throughout North
America, Latin America, and Asia Pacific, the business is now
standardizing on multichannel
Veeva CRM globally.

In addition to core Veeva CRM, the Healthcare business of Merck KGaA,
Darmstadt, Germany is expanding use of Veeva
CLM, Veeva
CRM Approved Email, and Veeva
CRM MyInsights across the world. These solutions will enable the
business to deliver a seamless customer experience across all channels,
including face-to-face, email, and web.

“Understanding our customers and delivering them the right information
at the right time through the right channel is key to our commercial
strategy,” said Chetak Buaria, global head of commercial excellence of
the Healthcare business at Merck KGaA, Darmstadt, Germany. “We are
unifying on a single global CRM solution to deliver on this vision with
Veeva as our trusted global partner.”

“Veeva is committed to helping life sciences companies drive effective
engagement with healthcare professionals,” said Paul Shawah, senior vice
president of Veeva
Commercial Cloud. “We are proud to team with the Healthcare business
of Merck KGaA, Darmstadt, Germany on their important mission to bring
innovative medicines to market.”

Join more than 1,700 life sciences professionals and experts at the
upcoming Veeva
Commercial & Medical Summit, May 13-15, in Philadelphia, PA. The
event is open to Veeva customers and invited guests. Register and view
the agenda at veeva.com/Summit.

Additional Information

For more on Veeva Vault CRM Suite, visit: veeva.com/CRM-suite
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva serves more than 700 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,
visit veeva.com.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology
company, operates across healthcare, life science and performance
materials. Around 52,000 employees work to make a positive difference to
millions of people’s lives every day by creating more joyful and
sustainable ways to live. From advancing gene editing technologies and
discovering unique ways to treat the most challenging diseases to
enabling the intelligence of devices – the company is everywhere. In
2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion
in 66 countries.

The company holds the global rights to the name and trademark “Merck”
internationally. The only exceptions are the United States and Canada,
where the business sectors of Merck KGaA, Darmstadt, Germany operate as
EMD Serono in healthcare, MilliporeSigma in life science, and EMD
Performance Materials. Since its founding 1668, scientific exploration
and responsible entrepreneurship have been key to the company’s
technological and scientific advances. To this day, the founding family
remains the majority owner of the publicly listed company.

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-K for the period ended January 31, 2019. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.

Contacts

Roger Villareal
Veeva Systems
925-264-8885
[email protected]

Kiran May
Veeva Systems
+44-796-643-2912
[email protected]